Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Терапия ранних рецидивов хронического лимфолейкоза: развитие проблемы
Терапия ранних рецидивов хронического лимфолейкоза: развитие проблемы
Терапия ранних рецидивов хронического лимфолейкоза: развитие проблемы. Современная Онкология. 2021;23(4):610–611. DOI: 10.26442/18151434.2021.4.201331
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В течение 2021 г. Российским обществом онкогематологов при поддержке компании «Эббви» реализован проект, позволяющий российским гематологам обсудить возможности оптимизации подходов к терапии ранних рецидивов хронического лимфолейкоза. На финальном совещании сформулировано консолидированное мнение специалистов для нескольких клинических ситуаций.
Ключевые слова: хронический лимфолейкоз, ранние рецидивы, таргетная терапия, венетоклакс
Keywords: chronic lymphocytic leukemia, early relapses, targeted therapy, venetoclax
Ключевые слова: хронический лимфолейкоз, ранние рецидивы, таргетная терапия, венетоклакс
________________________________________________
Keywords: chronic lymphocytic leukemia, early relapses, targeted therapy, venetoclax
Полный текст
Список литературы
1. Kater AP, Kipps TJ, Eichhorst B, et al. Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). ASH. 2020; Oral presentation 125.
2. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-7.
DOI:10.1182/blood-2014-09-603670
3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80-7. DOI:10.1001/jamaoncol.2014.218
4. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-36. DOI:10.1056/NEJMoa1815281
5. Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019;37(4):269-77. DOI:10.1200/JCO.18.01580
6. Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020;38(34):4042-54. DOI:10.1200/JCO.20.00948
2. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-7.
DOI:10.1182/blood-2014-09-603670
3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80-7. DOI:10.1001/jamaoncol.2014.218
4. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-36. DOI:10.1056/NEJMoa1815281
5. Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019;37(4):269-77. DOI:10.1200/JCO.18.01580
6. Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020;38(34):4042-54. DOI:10.1200/JCO.20.00948
2. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-7.
DOI:10.1182/blood-2014-09-603670
3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80-7. DOI:10.1001/jamaoncol.2014.218
4. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-36. DOI:10.1056/NEJMoa1815281
5. Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019;37(4):269-77. DOI:10.1200/JCO.18.01580
6. Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020;38(34):4042-54. DOI:10.1200/JCO.20.00948
________________________________________________
2. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-7.
DOI:10.1182/blood-2014-09-603670
3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015;1(1):80-7. DOI:10.1001/jamaoncol.2014.218
4. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225-36. DOI:10.1056/NEJMoa1815281
5. Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019;37(4):269-77. DOI:10.1200/JCO.18.01580
6. Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020;38(34):4042-54. DOI:10.1200/JCO.20.00948
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.